Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL GAELLE MONTEL PHARMACIEN : revenue, balance sheet and financial ratios

SPFPL GAELLE MONTEL PHARMACIEN is a French company founded 4 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in BELLEVILLE-EN-BEAUJOLAIS (69220), this company of category PME shows in 2025 a net income positive of 17 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL GAELLE MONTEL PHARMACIEN (SIREN 913960928)
Indicator 2025 2024 2023
Revenue N/C N/C N/C
Net income 16 902 € 16 081 € -10 676 €
EBITDA -1 965 € -2 104 € -10 385 €
Net margin N/C N/C N/C

Revenue and income statement

In 2025, SPFPL GAELLE MONTEL PHARMACIEN generates positive net income of 17 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

EBITDA (2025) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-1 965 €

EBIT (2025) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-1 965 €

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

16 902 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 2045%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 5%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 28.2 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

2044.708%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

4.663%

Repayment capacity (2025) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

28.195

Solvency indicators evolution
SPFPL GAELLE MONTEL PHARMACIEN

Sector positioning

Debt ratio
2044.71 2025
2023
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Watch +51 pts over 3 years

In 2025, the debt ratio of SPFPL GAELLE MONTEL PHARM... (2044.71) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
4.66% 2025
2023
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Average

In 2025, the financial autonomy of SPFPL GAELLE MONTEL PHARM... (4.7%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
28.2 years 2025
2023
2024
2025
Q1: 0.0 years
Med: 0.77 years
Q3: 6.12 years
Average +50 pts over 3 years

In 2025, the repayment capacity of SPFPL GAELLE MONTEL PHARM... (28.20) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

Interest coverage (2025) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-47.532

Liquidity indicators evolution
SPFPL GAELLE MONTEL PHARMACIEN

Sector positioning

Interest coverage
-47.53x 2025
2023
2024
2025
Q1: -191.54x
Med: -25.42x
Q3: 0.0x
Average -10 pts over 3 years

In 2025, the interest coverage of SPFPL GAELLE MONTEL PHARM... (-47.5x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Positioning of SPFPL GAELLE MONTEL PHARMACIEN in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Based on 170 transactions of similar company sales (all years), the value of SPFPL GAELLE MONTEL PHARMACIEN is estimated at 175 219 € (range 108 610€ - 272 521€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
108k€ 175k€ 272k€
175 219 € Range: 108 610€ - 272 521€
NAF 5 all-time

Valuation method used

Net Income Multiple
16 902 € × 10.4x = 175 220 €
Range: 108 611€ - 272 522€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare SPFPL GAELLE MONTEL PHARMACIEN with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about SPFPL GAELLE MONTEL PHARMACIEN

What is the revenue of SPFPL GAELLE MONTEL PHARMACIEN ?

The revenue of SPFPL GAELLE MONTEL PHARMACIEN is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL GAELLE MONTEL PHARMACIEN profitable?

Yes, SPFPL GAELLE MONTEL PHARMACIEN generated a net profit of 17 k€ in 2025.

Where is the headquarters of SPFPL GAELLE MONTEL PHARMACIEN ?

The headquarters of SPFPL GAELLE MONTEL PHARMACIEN is located in BELLEVILLE-EN-BEAUJOLAIS (69220), in the department Rhone.

Where to find the tax return of SPFPL GAELLE MONTEL PHARMACIEN ?

The tax return of SPFPL GAELLE MONTEL PHARMACIEN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL GAELLE MONTEL PHARMACIEN operate?

SPFPL GAELLE MONTEL PHARMACIEN operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.